Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 93   

Articles published

PSTI 2.79 -0.06 (-2.11%)
price chart
MLV Maintains Buy on Pluristem Therapeutics Inc. as PLX-R18 Strategy ...
In a research report published Tuesday, MLV analyst Vernon Bernardino maintained a Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a price target of $6.00, which represents a potential upside of 113% from where the stock is currently ...
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Monday Pre-Market Insights: Pluristem Therapeutics Inc. (PSTI), Juno ...
Pluristem Therapeutics Inc. (NASDAQ:PSTI) shares rose 8.58% to $2.91 after the biopharmaceutical company announced that its PLX cells were selected for the Adaptive Pathways pilot project through the European Medicines Agency.
Pluristem Therapeutics: A Biotech Scam Promoted By A Bucket Shop
Pluristem Therapeutics Inc. (NASDAQ:PSTI) is a clinical-stage company engaged in development of cell therapy products for the treatment of life threatening diseases.
Pluristem Therapeutics (PSTI) Reports Data from Phase I/II PLX-PAD Trail  StreetInsider.com
Pluristem Announces Significant New Finding From Its Phase I/II Muscle ...  GlobeNewswire (press release)
Pluristem Therapeutics' (PSTI) PLX Cells Selected for EMA Adaptive Pathways ...
Pluristem Therapeutics Inc. (Nasdaq: PSTI) today announced a significant advancement to its clinical development plan: the PLX cell program in critical limb ischemia has been selected for the European Medicines Agency's Adaptive Pathways pilot project.
Significant Progress for Pluristem: PLX Cells Were Selected for European ...  GlobeNewswire (press release)
Pluristem Therapeutics Inc. (PSTI): The Bull Case For Pluristem Therapeutics
One of the problems that the technology faced was that the cell culture process created degradation in the quality of their therapeutic ability.
Related articles »  
Hot News: Pluristem Therapeutics, Inc. (NASDAQ:PSTI), Texas Instruments Inc ...
Pluristem Therapeutics, Inc. (NASDAQ:PSTI) belongs to Healthcare sector. Its weekly performance is 6.34%. On last trading day company shares ended up $2.85.
Pluristem Therapeutics Inc. (NASDAQ:PSTI) a Buy: MLV & Co
In a research note issued to investors, Vernon Bernardino at MLV & Co Reiterated their Buy rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI). The analyst placed a $6.00 price target on the stock which indicates a 105.48% upside to the last closing price.
Top Stories in Biotech This Morning: Pluristem Therapeutics, Inc, Rigel ...
This is the second regulatory approval for the company's 3D cell manufacturing process, having received approval in Germany last January.
Related articles »  
Pluristem Therapeutics Inc. (PSTI): Mesoblast Is No Match For Pluristem's IP ...
Last week, Pluristem Therapeutics Inc. (NASDAQ:PSTI) won a method of use patent in Australia for its PLX cells in ischemia, where obstruction of blood vessels to an organ causes tissue death.
Related articles »